Risk Assessment for Pharmaceutical Products

  • Jeanne M. Manson
Conference paper


As described in previous talks, pharmaceutical products are tested in a lengthy and highly redundant series of tests to identify whether they produce reproductive toxicity in laboratory animals. Considerable progress has been made in improving the design of these studies, and draft guidelines have been promulgated which reduce the redundancy and increase the flexibility of reproductive toxicity tests for drug safety evaluation (Bass et al. 1991; Lumley and Walker, 1991). With improvement in the design of animal studies, it is now possible to turn our attention to the risk assessment process for Pharmaceuticals, the process in which results from animal studies are used to predict whether adverse effects will occur in humans. The perspective I will take is that of a laboratory investigator who condenses the results from animal studies into the narrowly defined categories for use of a drug in pregnancy. This is only the first step in the risk assessment process, and subsequently clinical, legal and regulatory perspectives must be obtained on the potential uses and abuses of the drug during human pregnancy before the final label is produced.


Developmental Toxicity Human Pregnancy Pregnancy Category Trimester Exposure Maternal Toxicity 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Bass R, Ulbrich B, Hildebrandt A, Weissinger J, Doi O, Baeder C, Fumero S, Harada Y, Lehman H, Manson J, Neubert D, Omori Y, Palmer A, Sullivan F, Takayama S, Tanimura T (1991) Draft guidelines on detection of toxicity to reproduction for medicinal products. Adverse Drug React Toxicol Rev 9(3): 127–141.Google Scholar
  2. Broughton Pipkin F, Symonds EM, Turner SR (1982) The effect of captopril (SQ 14, 225) upon mother and fetus in the chronically canulated ewe and in the pregnant rabbit. J Physiol (London) 323: 415–422.Google Scholar
  3. Broughton Pipkin F, Wallace CP (1986) The effect of enalapril (MK-421), an angiotensin converting enzyme inhibitor, on the conscious pregnant ewe and her fetus. Brit J Pharmacol 87: 533–542.Google Scholar
  4. Clark R, Robertson R, Minsker D, Cohen S, Tocco D, Allen H, James M, Bokelman D (1984) Diflunisal-induced maternal anaemia as a cause of teratogenicity in rabbits. Teratology 30: 319–332.PubMedCrossRefGoogle Scholar
  5. Hall J, Guyton A, Jackson T, Coleman T, Lohmeier T, Trippodo N (1977) Control of glomerular filtration rate by renin angiotensin system. Am J Physiol 233: 366–372.Google Scholar
  6. Hanssens M, Keirse M, Vankelecom F, Van Assche F (1991) Fetal and neonatal effects of treatment with angiotensin converting enzyme inhibitors in pregnancy. Obstet Gynecol 78(1): 128–135.PubMedGoogle Scholar
  7. Lumley CE, Walker SR (1991) Current issues in reproductive and developmental toxicity: Can an international guideline be achieved. Quay Publishing, Lancaster, UK.Google Scholar
  8. Minsker DH, Bagdon W, MacDonald J, Robertson R, Bokelman D (1990) Maternotoxicity and fetotoxicity of an angiotensin converting enzyme inhibitor, enalapril, in rabbits. Fund Appl Toxicol 14: 461–470.CrossRefGoogle Scholar
  9. Physicians’ Desk Reference (PDR) (1992) ER Barnhart, New York.Google Scholar
  10. Pryde P, Nugent C, Sedman A, Barr M (1991) Ace inhibitor fetopathy. JAMA, in press.Google Scholar
  11. Robertson R (1984) Comparative ACE inhibitory activity of enalaprilat and captopril in anesthetized pregnant and nonpregnant rabbits. MSDRL memo May 29, 1984.Google Scholar
  12. Robertson RT, Minsker DH, Bokelman DL (1986) MK-421 (enalapril maleate): late gestation and lactation study in rats. Jpn Pharmacol Ther 14: 43–55.Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1992

Authors and Affiliations

  • Jeanne M. Manson

There are no affiliations available

Personalised recommendations